ViMRT
}  
 
Home   
< Docs   

 HBV mutation literature information.


  Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy.
 PMID: 19280622       2009       Hepatology (Baltimore, Md.)
Abstract: Entecavir (ETV) resistance (ETVr) results from HBV reverse transcriptase substitutions at positions T184, S202, or M250, which emerge in the presence of lamivudine (LVD) resistance substitutions M204I/V +/- L180M.


  Ultra-deep pyrosequencing of hepatitis B virus quasispecies from nucleoside and nucleotide reverse-transcriptase inhibitor (NRTI)-treated patients and NRTI-naive patients.
 PMID: 19301976       2009       The Journal of infectious diseases
Result: Among the NRTI-resistance mutations, M204I was detected in 1.3% of the sequence reads in the sample from subject A7; A181T and M204I were present in 1.0% of the sequence reads in the sample from subject E6.
Result: For sample A7, M204I was found in 1 of 64 clones sequenced by dideoxynucleotide sequencing; however, that clone had 2 stop codons and G-to-A hypermutation.
Result: For the sample from subject E6, A181T and M204I were each found in 1 of 80 molecular clones; the clone with M204I had G-to-A hypermutation and 2 stop codons.


  Evolution of hepatitis B virus polymerase mutations in a patient with HBeAg-positive chronic hepatitis B virus treated with sequential monotherapy and add-on nucleoside/nucleotide analogues.
 PMID: 19302908       2009       Clinical therapeutics
Abstract: A total of 9.1% (4/44) of the clones harbored the rtL180M + rtT184L + rtM204I mutations.
Abstract: At week 18 during LAM treatment, the rtM204I mutation became predominant, being present in 79.5% (35/44) of clones.
Abstract: At week 22 during ADV treatment, LAM-resistance mutations (rtL180M, rtT184L, rtM204I, rtV191I, and rtL229V) were not d


  Hepatitis B virus with the rtL80V/I mutation is associated with a poor response to adefovir dipivoxil therapy.
 PMID: 19323782       2009       Liver international
Abstract: BACKGROUND/AIMS: Lamivudine (LAM) resistance is frequently associated with various types of genomic changes in hepatitis B virus (HBV)-DNA including YMDD mutations (rtM204V/I).
Abstract: RESULTS: All the 97 patients had genotype C HBV associated with rtM204V/I mutations; 63 (65%) rtM204I, 27 (28%) rtM204V and seven (7%) both.
Abstract: The rtM204I and rtM204V variants were strongly associated with rtL80V/I and


  Frequent detection of hepatitis B virus variants associated with lamivudine resistance in treated South African patients infected chronically with different HBV genotypes.
 PMID: 19382250       2009       Journal of medical virology
Abstract: Of the 17 patients, 13 (76.5%) carried YMDD mutations: 7 with rtM204I (2 HBeAg-positive and 5 HBeAg-negative) and 6 with rtM204V (4 HBeAg-positive and 2 HBeAg-negative).


  Effect of HIV co-infection on mutation patterns of HBV in patients with lamivudine-resistant chronic hepatitis B.
 PMID: 19475624       2009       Journal of medical virology
Abstract: Eighty-nine patients infected with HBV (29 co-infected with HIV) with rtM204V or rtM204I mutations were included.


  Characterization of hepatitis B virus reverse transcriptase sequences in Chinese treatment naive patients.
 PMID: 19486254       2009       Journal of gastroenterology and hepatology
Abstract: The M204V/I mutation was found in 1.8% of the strains, 1.2% had L180M+ M204V/I, 0.6% had A181T/V, and only one had all three mutations.


  Clinical and virological responses to clevudine therapy in chronic hepatitis B patients: results at 1 year of an open-labelled prospective study.
 PMID: 19578244       2009       Antiviral therapy
Abstract: This patient had an HBV polymerase mutation, rtM204I.
Abstract: Viral breakthrough associated with the rtM204I mutation in the HBV polymerase gene occurs during long-term clevudine treatment.


  [Long-term clevudine therapy in nucleos(t)ide-naive and lamivudine-experienced patients with hepatitis B virus-related chronic liver diseases].
 PMID: 19581770       2009       The Korean journal of hepatology
Abstract: Proven sites of mutation of HBV DNA polymerase in naive patients were, for example, L80I, L180M, A181V/T, M204I and V207I.


  Prevalence, viral replication efficiency and antiviral drug susceptibility of rtQ215 polymerase mutations within the hepatitis B virus genome.
 PMID: 19586679       2009       Journal of hepatology
Abstract: Replication-competent HBV constructs containing the naturally occurring rtQ215H, rtQ215P and rtQ215S mutations were generated, and compared to wild-type, LAM- (rtM204I, rtL180M/rtM204V) and ADV-resistant (rtN236T) clones.



Browser Board

 Co-occurred Entities




   Filtrator